Atmospheric Pressure Cold Plasma for Moderate-to-severe Tinea Pedis

Launched by SHENYANG MEDICAL COLLEGE · Jun 30, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called atmospheric pressure cold plasma (CAP) for people with moderate to severe athlete’s foot, a common and contagious fungal infection of the feet. Athlete’s foot can cause redness, itching, peeling skin, and sometimes more serious problems, and it can be hard to treat with usual creams or medicines. CAP is a new technology that uses a gentle, cold form of plasma to kill the fungus and help the skin heal, without harming healthy tissue. The study aims to see if this treatment is safe and works well for people with tougher cases of athlete’s foot.

People who may join the study are adults between 18 and 70 years old who have a confirmed diagnosis of moderate to severe athlete’s foot, especially between the toes, with noticeable symptoms like redness and itching. Women who can become pregnant need to agree to use birth control during the study. People with serious health problems, recent use of certain medications, or who are pregnant or breastfeeding won’t be able to join. Participants will receive the CAP treatment and be monitored to check how well it works and if there are any side effects. This study is not yet recruiting, but it could offer a promising new option for those struggling with difficult-to-treat athlete’s foot.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 70 years, irrespective of sex.
• • Clinical diagnosis of interdigital tinea pedis (non-hyperkeratotic type), with or without extension to other areas, of moderate to severe intensity, defined as follows: target lesion(s) will have an erythema score of ≥2 and either a desquamation or pruritus score of ≥2, with a total score ≥4 (using a 0-3 scale for each item).
• • Positive direct potassium hydroxide (KOH) microscopic examination for dermatophytes.
• • Women of childbearing potential will agree to use effective contraception throughout the study period.
• • Written informed consent will be obtained prior to enrollment.
• Exclusion Criteria:
• • Severe bacterial infection or other dermatological conditions that may interfere with study assessments.
• • Serious cardiac, hepatic, or renal diseases, diabetes mellitus, or major psychiatric disorders.
• • Systemic corticosteroid or immunosuppressant use within the past 3 months.
• • Systemic antifungal agents within the past 2 months or topical antifungal agents within the past 2 weeks.
• • Pregnancy or breastfeeding.